WBA stock closed at $11.98 on the NASDAQ in the United States on 04 Mar 2026, making Walgreens Boots Alliance one of the market’s most active names by volume. Trading volume hit 452,081,061 shares versus an average of 16,940,296, a clear sign of heavy attention from traders. The price sits between the 50-day average $11.66 and the 200-day average $10.81, while market capitalization is $10,369,421,068. We use Meyka AI as an AI-powered market analysis platform to connect these flows to valuation, technicals and analyst signals for investors watching WBA stock

WBA stock: Market snapshot and price action

Walgreens Boots Alliance (WBA) closed $11.98 on NASDAQ at market close on 04 Mar 2026. Volume surged to 452,081,061 shares, or 26.69x relative volume, driving intraday range locked at $11.98. Year high is $13.25 and year low is $8.08. The stock is trading above its 50-day average $11.66 and 200-day average $10.81, which supports a short-term constructive price bias.

Recent headlines include price history and market mentions on investing sites; see the latest trading record on Investing.com and market coverage noting WBA’s index role on Investors.com.

Financials and valuation for WBA stock

Walgreens Boots Alliance reports trailing metrics showing mixed fundamentals. EPS is -7.29, producing a negative P/E of -1.64, and revenue per share TTM is 178.73. Key valuation ratios: Price/Sales 0.07, Price/Book 1.44, and EV/Revenue 0.25. Free cash flow per share TTM is 0.67, giving a P/FCF near 17.88.

The balance sheet carries leverage: debt to equity TTM is 4.04 and interest coverage is negative at -6.13, which elevates refinancing and cyclical risk. Current ratio is 0.60, indicating tighter short-term liquidity versus peers in the healthcare retail sector.

Technicals and trading flow on WBA stock

Momentum indicators show strong short-term activity: RSI is reported at 100.00 and ADX at 50.00, marking a strong trend and overbought reading. Keltner channels center at $11.93 with the upper band $12.26 and lower $11.60. On-balance volume (OBV) equals the day’s volume 452,081,061, reflecting the heavy flow into the stock.

Short-term technicals favor momentum traders but the extreme RSI warns of a possible pullback. The stock’s relative performance YTD is +30.36%, while one-year performance is +32.23%, showing recent strength versus multi-year declines.

Meyka AI rates WBA with a score out of 100 and forecast

Meyka AI rates WBA with a score out of 100: the model gives a score of 62.62 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The upgrade/downgrade consensus shows 1 Hold and 1 Sell from two tracked analysts.

Meyka AI’s forecast model projects $13.50 as a 12-month target for WBA stock. Versus the current $11.98, that implies an upside of 12.69%. Forecasts are model-based projections and not guarantees. Use the grade and forecast as context, not as investment advice.

Risks and opportunities for WBA stock

Primary risks include negative EPS (-7.29), high leverage (debt/equity 4.04), weak interest coverage (-6.13), and tight liquidity (current ratio 0.60). These metrics increase sensitivity to higher rates and profit margin pressure in retail pharmacy operations.

Opportunities include resilient retail network cash flows, stable same-store pharmacy demand, and potential operational improvement that could lift margins. Price is trading near multi-month support above the 200-day average $10.81, offering a defined risk level for traders and investors.

Analyst outlook, sector context and trading strategy

Analyst coverage on WBA stock is limited with no clear buy-side consensus; the crowd includes holdings and cautious sells. The healthcare retail sector shows defensive traits but tighter margins. Relative to peers, WBA’s Price/Sales 0.07 is low, suggesting value if earnings normalize.

For most-active traders, strategies include momentum entries on breakout above $12.25 with tight stops, or mean-reversion trades on pullbacks to the 200-day average $10.81. Long-term investors should weigh leverage and EPS recovery paths before committing capital.

Final Thoughts

Key takeaways on WBA stock: the market closed $11.98 on NASDAQ on 04 Mar 2026 with a large volume spike of 452,081,061 shares, marking it among the day’s most active names. Fundamentals remain challenged with EPS -7.29 and debt/equity 4.04, but valuation metrics like Price/Sales 0.07 and Price/Book 1.44 leave room for upside if operating profits recover. Meyka AI rates WBA with a score of 62.62/100 (Grade B, Suggestion: HOLD) and projects a 12-month model target of $13.50, implying +12.69% from today’s price. That projection is model-based and not a guarantee. Traders should balance technical momentum signals—RSI 100.00 and ADX 50.00—against structural company risks, and use clear stops given the company’s leverage and negative interest coverage. For real-time order flow and alerts, see our internal Meyka WBA page for live charts and updates

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.